Cancer Evolvability Determines Therapy Outcomes.
5 affiliations
- 1Department of Integrated Mathematical Oncology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
- 2Department of Cancer Biology University of South Florida Tampa Florida USA.
- 3Department of Mathematics City St. George's, University of London London UK.
- 4Department of Radiology H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
- 5Cancer Biology and Evolution Program Moffitt Cancer Center and Research Institute Tampa Florida USA.
Abstract
Cancer progression following treatment failure is an evolutionary process in which therapy acts as a selection pressure driving Darwinian selection on heritable variation to favor resistant clones. Heritable variation is a key determinant of how rapidly tumors can adapt to therapy. Heritable variation arises through various mechanisms such as genetic mutations, epigenetics, chromosomal rearrangements, and copy number variations, resulting in a lack of replicative fidelity. We consider evolvability as a property or trait of the cancer cells that influences the rate at which fitness-relevant heritable variation is generated. Using this as our definition, we present an evolutionary game-theoretic model to evaluate how evolvability shapes resistance dynamics under two treatment modalities: targeted therapy and chemotherapy. We first compare cancer populations with fixed evolvabilities: low or high. Targeted therapy imposes a steep selection gradient, enabling rapid resistance evolution, while chemotherapy imposes a flatter selection gradient but drives tumors toward more extreme resistance strategies. We show that targeted therapy works better in cancers with low evolvability, whereas chemotherapy better controls cancers with high evolvability. We then extend the model to incorporate "plastic evolvability," in which cancer cells can adjust their evolvability in response to therapy-induced stress. In this case, cells fine-tune the trade-off between acquiring higher resistance and limiting the costs of resistance and evolvability. Plastic evolvability sustains a higher tumor burden than fixed-evolvability. To address the challenge of plastic evolvability, we develop and simulate an evolutionary double bind using sequential cycles of chemotherapy and targeted therapy. With an appropriate sequence and timing, the double bind can drive cancers with plastic evolvability to extinction. Our results highlight the importance of evolvability in shaping treatment response and underscore the need to incorporate evolutionary principles into therapy design.
Related
- Impact of an early extended rehabilitation programme combining individually tailored nutrition and physical activity on patient outcomes after invasive mechanical ventilation and vasopressor therapy in the ICU: design and conduct of a multicentre, randomised, controlled, open-label, assessor-blinded trial (NUTRIREA-4)
- Familial Pancreatic Cancer Associated with a Shared BRIP1 Variant: Implications for Homologous Recombination Deficiency and Targeted Therapy
- Vault Packaging Dynamics: Cargo Loading Stabilizes MVP Conformation for High-Payload Cytokine Delivery in Cancer Therapy
- FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
- Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
BibTeX
@article{bhattacharya2026cancer,
title = {{Cancer Evolvability Determines Therapy Outcomes.}},
author = {Ranjini Bhattacharya and Anuraag Bukkuri and Robert A Gatenby and Joel S Brown},
journal = {Evolutionary applications},
year = {2026},
month = oct,
doi = {10.1111/eva.70320},
url = {https://europepmc.org/article/MED/42948278},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cancer Evolvability Determines Therapy Outcomes.
AU - Ranjini Bhattacharya
AU - Anuraag Bukkuri
AU - Robert A Gatenby
AU - Joel S Brown
PY - 2026
DA - 2026/10/25
JO - Evolutionary applications
DO - 10.1111/eva.70320
UR - https://europepmc.org/article/MED/42948278
AB - Cancer progression following treatment failure is an evolutionary process in which therapy acts as a selection pressure driving Darwinian selection on heritable variation to favor resistant clones. Heritable variation is a key determinant of how rapidly tumors can adapt to therapy. Heritable variation arises through various mechanisms such as genetic mutations, epigenetics, chromosomal rearrangements, and copy number variations, resulting in a lack of replicative fidelity. We consider evolvability as a property or trait of the cancer cells that influences the rate at which fitness-relevant heritable variation is generated. Using this as our definition, we present an evolutionary game-theoretic model to evaluate how evolvability shapes resistance dynamics under two treatment modalities: targeted therapy and chemotherapy. We first compare cancer populations with fixed evolvabilities: low or high. Targeted therapy imposes a steep selection gradient, enabling rapid resistance evolution, while chemotherapy imposes a flatter selection gradient but drives tumors toward more extreme resistance strategies. We show that targeted therapy works better in cancers with low evolvability, whereas chemotherapy better controls cancers with high evolvability. We then extend the model to incorporate "plastic evolvability," in which cancer cells can adjust their evolvability in response to therapy-induced stress. In this case, cells fine-tune the trade-off between acquiring higher resistance and limiting the costs of resistance and evolvability. Plastic evolvability sustains a higher tumor burden than fixed-evolvability. To address the challenge of plastic evolvability, we develop and simulate an evolutionary double bind using sequential cycles of chemotherapy and targeted therapy. With an appropriate sequence and timing, the double bind can drive cancers with plastic evolvability to extinction. Our results highlight the importance of evolvability in shaping treatment response and underscore the need to incorporate evolutionary principles into therapy design.
SN - 1752-4571
ER -